Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 101,900 shares, a drop of 21.6% from the January 15th total of 130,000 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 85,200 shares, the days-to-cover ratio is currently 1.2 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DRTS. Levin Capital Strategies L.P. boosted its position in Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock worth $975,000 after purchasing an additional 7,189 shares during the last quarter. Renaissance Technologies LLC boosted its position in Alpha Tau Medical by 188.7% in the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock worth $127,000 after purchasing an additional 26,800 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Alpha Tau Medical by 112.6% in the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock worth $151,000 after purchasing an additional 25,770 shares during the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

Alpha Tau Medical Price Performance

NASDAQ DRTS traded up $0.08 during trading hours on Friday, hitting $3.14. The company’s stock had a trading volume of 31,523 shares, compared to its average volume of 148,702. The company has a market cap of $219.55 million, a P/E ratio of -7.30 and a beta of 0.83. The company’s 50 day simple moving average is $3.39 and its two-hundred day simple moving average is $2.69. Alpha Tau Medical has a 12 month low of $1.75 and a 12 month high of $4.39.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Alpha Tau Medical in a report on Friday, November 22nd.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.